U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Fusipim Sdn. Bhd. - 485814 - 07/27/2017
  1. Warning Letters

CLOSEOUT LETTER

Fusipim Sdn. Bhd. MARCS-CMS 485814 —

Recipient:
Fusipim Sdn. Bhd.

United States

Issuing Office:

United States

 

   

Black HHS-Blue FDA Logo

 

 
 
5001 Campus Drive
College Park, MD 20740 

July 27, 2017

Mr. Ben Eng
Executive Director
Fusipim Sdn. Bhd.
Lot 9224, Batu 4 1/2, Panchang Bedena
Sungai Besar, Selangor 45300
Malaysia

Dear Mr. Eng:

The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter # 485814, issued February 5, 2016. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

Maria Corpuz
Supervisor
Food Adulteration Assessment Branch
Division of Enforcement
Office of Compliance
Center for Food Safety
     and Applied Nutrition 

Back to Top